1-13 of 13
Matthew S. Davids
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PI3K Inhibitors in Hematology: When One Door Closes…

Sigrid S. Skånland, Klaus Okkenhaug, Matthew S. Davids
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3667–3675.
https://doi.org/10.1158/1078-0432.CCR-24-0967
Published: 03 September 2024
View article titled, PI3K Inhibitors in Hematology: When One Door Closes…
Open the PDF for PI3K Inhibitors in Hematology: When One Door Closes… in another window
Journal Articles

First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors

Nehal J. Lakhani, Drew Rasco, Hengbang Wang, Lichuang Men, Eric Liang, Tommy Fu, Mary C. Collins, Ping Min, Yan Yin, Matthew S. Davids, Dajun Yang, Yifan Zhai
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (3): 506–521.
https://doi.org/10.1158/1078-0432.CCR-23-1525
Published: 01 February 2024
View article titled, First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors
Open the PDF for First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Overcoming Resistance in Chronic Lymphocytic Leukemia—Maybe Less Is More?

Othman Al-Sawaf, Matthew S. Davids
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (3): 471–473.
https://doi.org/10.1158/1078-0432.CCR-23-2872
Published: 01 February 2024
View article titled, Overcoming Resistance in Chronic Lymphocytic Leukemia—Maybe Less Is More?
Open the PDF for Overcoming Resistance in Chronic Lymphocytic Leukemia—Maybe Less Is More? in another window
Journal Articles

Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

Sikander Ailawadhi, Zi Chen, Bo Huang, Aneel Paulus, Mary C. Collins, Lei (Tommy) Fu, Mingyu Li, Mohammad Ahmad, Lichuang Men, Hengbang Wang, Matthew S. Davids, Eric Liang, Divya J. Mekala, Zhicong He, Masa Lasica, Costas K. Yannakou, Ricardo Parrondo, Laura Glass, Dajun Yang, Asher Chanan-Khan, Yifan Zhai
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (13): 2385–2393.
https://doi.org/10.1158/1078-0432.CCR-22-3321
Published: 05 July 2023
View article titled, Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Open the PDF for Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial in another window
Includes: Supplementary data
Journal Articles

Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)

Anthony R. Mato, Matthew S. Davids, Jeff Sharman, Lindsey E. Roeker, Neil Kay, Arnon P. Kater, Kerry Rogers, Meghan C. Thompson, Joanna Rhodes, Andre Goy, Alan Skarbnik, Stephen J. Schuster, Constantine S. Tam, Toby A. Eyre, Susan O'Brien, Chadi Nabhan, Nicole Lamanna, Clare Sun, Mazyar Shadman, John M. Pagel, Chaitra Ujjani, Danielle Brander, Catherine C. Coombs, Nitin Jain, Chan Y. Cheah, Jennifer R. Brown, John F. Seymour, Jennifer A. Woyach
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 603–608.
https://doi.org/10.1158/1078-0432.CCR-21-1237
Published: 15 February 2022
View article titled, Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)
Open the PDF for Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare) in another window
Journal Articles

Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study

Matthew S. Davids, Andrew W. Roberts, Vaishalee P. Kenkre, William G. Wierda, Abhijeet Kumar, Thomas J. Kipps, Michelle Boyer, Ahmed Hamed Salem, John C. Pesko, Jennifer A. Arzt, Margaret Mantas, Su Y. Kim, John F. Seymour
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4690–4695.
https://doi.org/10.1158/1078-0432.CCR-20-4842
Published: 01 September 2021
View article titled, Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study
Open the PDF for Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study in another window
Includes: Supplementary data
Journal Articles

BTK Inhibitors in Cancer Patients with COVID-19: “The Winner Will be the One Who Controls That Chaos” (Napoleon Bonaparte)

Elise A. Chong, Lindsey E. Roeker, Mazyar Shadman, Matthew S. Davids, Stephen J. Schuster, Anthony R. Mato
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (14): 3514–3516.
https://doi.org/10.1158/1078-0432.CCR-20-1427
Published: 15 July 2020
View article titled, BTK Inhibitors in Cancer Patients with COVID-19: “The Winner Will be the One Who Controls That Chaos” (Napoleon Bonaparte)
Open the PDF for BTK Inhibitors in Cancer Patients with COVID-19: “The Winner Will be the One Who Controls That Chaos” (Napoleon Bonaparte) in another window
Journal Articles

Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

Matthew S. Davids, Bryone J. Kuss, Peter Hillmen, Marco Montillo, Carol Moreno, James Essell, Nicole Lamanna, Zsolt Nagy, Constantine S. Tam, Stephan Stilgenbauer, Paolo Ghia, Julio Delgado, Stephanie Lustgarten, David T. Weaver, Hagop Youssoufian, Ulrich Jäger
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (9): 2096–2103.
https://doi.org/10.1158/1078-0432.CCR-19-3061
Published: 01 May 2020
View article titled, Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
Open the PDF for Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study in another window
Includes: Supplementary data
Journal Articles

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report

Haesook T. Kim, Kwang Woo Ahn, Zhen-Huan Hu, Matthew S. Davids, Virginia O. Volpe, Joseph H. Antin, Mohamed L. Sorror, Mazyar Shadman, Oliver Press, Joseph Pidala, William Hogan, Robert Negrin, Steven Devine, Joseph Uberti, Edward Agura, Richard Nash, Jayesh Mehta, Joseph McGuirk, Stephen Forman, Amelia Langston, Sergio A. Giralt, Miguel-Angel Perales, Minoo Battiwalla, Gregory A. Hale, Robert Peter Gale, David I. Marks, Mehdi Hamadani, Sid Ganguly, Ulrike Bacher, Hillard Lazarus, Ran Reshef, Gerhard C. Hildebrandt, Yoshihiro Inamoto, Jean-Yves Cahn, Melhem Solh, Mohamed A. Kharfan-Dabaja, Nilanjan Ghosh, Ayman Saad, Mahmoud Aljurf, Harry C. Schouten, Brian T. Hill, Attaphol Pawarode, Tamila Kindwall-Keller, Nakhle Saba, Edward A. Copelan, Sunita Nathan, Amer Beitinjaneh, Bipin N. Savani, Jan Cerny, Michael R. Grunwald, Jean Yared, Baldeep M. Wirk, Taiga Nishihori, Saurabh Chhabra, Richard F. Olsson, Asad Bashey, Usama Gergis, Uday Popat, Ronald Sobecks, Edwin Alyea, Wael Saber, Jennifer R. Brown
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (16): 5143–5155.
https://doi.org/10.1158/1078-0432.CCR-18-3988
Published: 15 August 2019
View article titled, Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report
Open the PDF for Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report in another window
Includes: Supplementary data
Journal Articles

Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Matthew S. Davids, Michael Hallek, William Wierda, Andrew W. Roberts, Stephan Stilgenbauer, Jeffrey A. Jones, John F. Gerecitano, Su Young Kim, Jalaja Potluri, Todd Busman, Andrea Best, Maria E. Verdugo, Elisa Cerri, Monali Desai, Peter Hillmen, John F. Seymour
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (18): 4371–4379.
https://doi.org/10.1158/1078-0432.CCR-17-3761
Published: 14 September 2018
View article titled, Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Open the PDF for Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia in another window
Includes: Supplementary data
Journal Articles

Abstract 17: In situ immune expression signatures before and after ipilimumab therapy for relapsed acute myeloid leukemia after allogeneic stem cell transplantation

Pavan Bachireddy, Matthew S. Davids, Michael S. Rooney, Michaela Bowden, Chensheng W. Zhou, Scott J. Rodig, Vincent Ho, Joseph Antin, John Koreth, Edwin Alyea, Robert J. Soiffer, Catherine J. Wu
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24_Supplement): 17.
https://doi.org/10.1158/1557-3265.HEMMAL17-17
Published: 14 December 2017
View article titled, Abstract 17: In situ immune expression signatures before and after ipilimumab therapy for relapsed acute myeloid leukemia after allogeneic stem cell transplantation
Journal Articles

BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis

Christopher J. Gibson, Matthew S. Davids
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (22): 5021–5029.
https://doi.org/10.1158/1078-0432.CCR-15-0364
Published: 12 November 2015
View article titled, BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis
Open the PDF for BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis in another window
Journal Articles

Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma

Jennifer R. Brown, Matthew S. Davids, Jordi Rodon, Pau Abrisqueta, Siddha N. Kasar, Joanne Lager, Jason Jiang, Coumaran Egile, Farrukh T. Awan
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (14): 3160–3169.
https://doi.org/10.1158/1078-0432.CCR-14-3262
Published: 14 July 2015
View article titled, Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma
Open the PDF for Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma in another window
Includes: Supplementary data